Genentech, Inc.

3 articles with Genentech, Inc.

• FDA Approves Genentech’s Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders

  9/27/2019

  Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients 2 years of age and older.

• Genentech’s Tecentriq (Atezolizumab) Improves Overall Survival as a First-line Monotherapy in Certain People With Advanced Non-small Cell Lung Cancer

  9/27/2019

  Genentech, a member of the Roche Group, announced positive data from the Phase III IMpower110 study evaluating Tecentriq® as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations.

• FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels

  9/27/2019

  The U.S. Food and Drug Administration approved Rituxan injection to treat granulomatosis with polyangiitis and microscopic polyangiitis in children 2 years of age and older in combination with glucocorticoids.